ROME Therapeutics

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

ROME Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $7.2B in funding across 36 round(s). With a team of 11-50 employees, ROME Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - ROME Therapeutics, raised $72.0M. Discover more about their projects, partnerships, and impact on our platform.